| 1.6 -0.08 (-4.76%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.81 |
1-year : | 3.43 |
| Resists | First : | 2.41 |
Second : | 2.94 |
| Pivot price | 2.08 |
|||
| Supports | First : | 1.55 | Second : | 1.29 |
| MAs | MA(5) : | 1.65 |
MA(20) : | 2.17 |
| MA(100) : | 1.4  |
MA(250) : | 1.23 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 5.6 |
D(3) : | 5.2 |
| RSI | RSI(14): 33.8 |
|||
| 52-week | High : | 2.94 | Low : | 0.74 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ IFRX ] has closed above bottom band by 17.9%. Bollinger Bands are 187% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.74 - 1.75 | 1.75 - 1.76 |
| Low: | 1.57 - 1.58 | 1.58 - 1.6 |
| Close: | 1.58 - 1.6 | 1.6 - 1.62 |
InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The company's focus on C5a stems from its critical role as an inflammatory mediator implicated in the progression of various autoimmune and inflammatory diseases. Its primary product candidate, vilobelimab, is an innovative, first-in-class anti-C5a monoclonal antibody delivered intravenously. Vilobelimab has progressed through several clinical stages for multiple indications: It has successfully completed a Phase III clinical trial for hidradenitis suppurativa (HS), a rare, chronic, and debilitating systemic inflammatory skin condition. It is currently undergoing Phase II trials for anti-neutrophil cytoplasm antibody associated vasculitis (AAV), a rare and life-threatening autoimmune disorder, and for PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC). An exploratory Phase IIa study is also underway for pyoderma gangraenosum (PG), a chronic inflammatory skin disorder. Beyond its lead candidate, InflaRx is also advancing INF904, an oral, small molecule drug candidate targeting undisclosed chronic inflammatory and autoimmune diseases, and IFX002, which is in preclinical development for chronic inflammation and autoimmune conditions. Strategic collaborations include a co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. and a clinical trial collaboration and supply agreement with Merck & Co. Inc. Established in 2007, the company, initially known as Fireman B.V., officially became InflaRx N.V. in 2017. It maintains its headquarters in Jena, Germany, with operations extending to the United States.
Wed, 10 Jun 2026
What Do Analysts Say About InflaRx N.V. (IFRX)? - Yahoo Finance
Fri, 05 Jun 2026
INFLARX NV (IFRX) Stock Chart - ChartMill
Sun, 31 May 2026
Here’s Why InflaRx (IFRX) is Among the 10 Most Volatile Penny Stocks to Buy Now - Yahoo Finance
Thu, 14 May 2026
Farallon funds and managers report shared stakes in InflaRx (IFRX) - Stock Titan
Fri, 08 May 2026
75 million new InflaRx shares raise cash to fund drug pipeline - Stock Titan
Fri, 08 May 2026
InflaRx N.V. Completes $150 Million Underwritten Offering of Ordinary Shares to Advance Pipeline Activities - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 147 (M) |
| Held by Insiders | 5.547e+007 (%) |
| Held by Institutions | 2.9 (%) |
| Shares Short | 1,810 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.243e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -144 % |
| Return on Assets (ttm) | 769.8 % |
| Return on Equity (ttm) | -39.1 % |
| Qtrly Rev. Growth | 29330 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -32.77 |
| EBITDA (p.s.) | -2.96311e+006 |
| Qtrly Earnings Growth | -0.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -29 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.05 |
| Price to Cash Flow | 6.61 |
| Dividend | 0 |
| Forward Dividend | 6.04e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|